TABLE 3.

Adverse events of AIT in patients without symptoms to suspect COVID‐19 (initiation and maintenance) (Questions 18–21).

Question 18: For patients receiving SCIT in the initiation period:
SCIT was well tolerated	330	95.7
SCIT lead to significant adverse event	15	4.3
Question 19: For patients receiving SLIT in the initiation period:
SLIT was well tolerated	310	89.9
SLIT lead to significant adverse event	35	10.1
Question 20: For patients receiving SCIT in the maintenance period:
SCIT was well tolerated	338	98
SCIT lead to significant adverse event	7	2
Question 21: For patients receiving SLIT in the maintenance period:
SLIT was well tolerated	323	93.6
SLIT lead to significant adverse event	22	6.4

Abbreviations: SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy.